| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/14/2006 | CA2597213A1 Compositions and methods for treating or preventing flaviviridae infections |
| 09/13/2006 | EP1700921A2 Regulation of a human asparagine-hydroxylase |
| 09/13/2006 | EP1700606A1 Therapies for chronic renal failure using one or more integrin antagonists |
| 09/13/2006 | EP1700603A2 Immunostimulatory nucleic acids |
| 09/13/2006 | EP1700602A1 Pharmaceutical composition for use in hormone replacement therapy |
| 09/13/2006 | EP1700601A2 Use of dextromethorphan and an oxidase inhibitor for weaning patients from narcotics and anti-despressants |
| 09/13/2006 | EP1699489A2 Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor |
| 09/13/2006 | EP1699488A2 Therapeutic combination for cognition enhancement and psychotic disorders |
| 09/13/2006 | EP1699487A2 Novel anti-dc-sign antibodies |
| 09/13/2006 | EP1699477A2 Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
| 09/13/2006 | EP1699473A2 Solvent for biogenic active pharmaceutical ingredients |
| 09/13/2006 | EP1699468A1 Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis |
| 09/13/2006 | EP1699463A1 Pharmaceutical composition for treating and preventing cancer comprising cinnamoni cortex extract and zizyphi fructus extract |
| 09/13/2006 | EP1699462A1 Reduction of toxicity of multi-targeting antifolates |
| 09/13/2006 | EP1699451A2 Use of at least one effector of glutathione metabolism, together with alpha-liponic acid for the treatment of lung deseases |
| 09/13/2006 | EP1699450A2 Co-administration of dopamine-receptor binding compounds |
| 09/13/2006 | EP1532145B1 Pyrazole compositions useful as inhibitors of gsk-3 |
| 09/13/2006 | EP1497662B1 Uses of the carbamoyl phosphate synthesis 1 (cps 1) and the fragments thereof for the diagnosis of sepsis |
| 09/13/2006 | EP1487424B1 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases |
| 09/13/2006 | EP1414465B1 Use of inhibitors of progesterone receptor for treating steroid resistant breast cancer |
| 09/13/2006 | EP1401417A4 Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| 09/13/2006 | EP1360504B1 Method for screening compounds for activity in treating an osteoclast related bone disease |
| 09/13/2006 | EP1343486B1 Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration |
| 09/13/2006 | EP1339840B1 Schizophrenia-related voltage-gated ion channel gene and protein |
| 09/13/2006 | EP1305635B1 Methods to identify compounds that modulate rage |
| 09/13/2006 | EP1305406B1 Modulation of gamma-secretase activity |
| 09/13/2006 | EP1284720B1 L-fmau for the treatment of hepatitis delta viral infection |
| 09/13/2006 | EP1246617B1 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer |
| 09/13/2006 | EP1229938B1 Potentiation of the activity of sn-38 prodrugs |
| 09/13/2006 | EP1224288B1 Processed human chemokine phc-1 |
| 09/13/2006 | EP1200040B8 Two-component composition for cosmetic or pharmaceutical use |
| 09/13/2006 | EP1163272B1 Antibodies specific for cyp1b1 |
| 09/13/2006 | EP1095062B1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 09/13/2006 | EP1079807B1 Use of preparations for the application of antiseptic agents and/or agents promoting the healing of wounds to the lower respiratory tract |
| 09/13/2006 | EP0917462B1 Cell adhesion inhibitors |
| 09/13/2006 | CN1832948A 1- alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 09/13/2006 | CN1832934A Benzoxazepine-based compound |
| 09/13/2006 | CN1832758A Pharmaceutical composition |
| 09/13/2006 | CN1832757A Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| 09/13/2006 | CN1832749A Viscosity-Stable bismuth-containing pharmaceutical compositions. |
| 09/13/2006 | CN1832747A Combinations comprising staurosporines |
| 09/13/2006 | CN1832732A Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease |
| 09/13/2006 | CN1275041C Prognostic indicator |
| 09/13/2006 | CN1274676C Quinoline and quinazoline derivatives |
| 09/13/2006 | CN1274668C Salts of nateglinide |
| 09/13/2006 | CN1274365C Medicinal compositions for angiogenic therapy |
| 09/13/2006 | CN1274305C Pharmaceutical composition with combined active agents and methods for using the same |
| 09/12/2006 | US7105673 Cardioprotective phosphonates and malonates |
| 09/12/2006 | US7105641 Immunoglobulin for binding monocyte chemoattractant protein-1(MCP-1) and preventing and/or treating atherosclerosis and cancer ; antitumor agents |
| 09/12/2006 | US7105576 Synergistic effects of nuclear transcription factor NF-κB inhibitors and anti-neoplastic agents |
| 09/12/2006 | US7105575 Methods for the treatment of neuro- disorders using aminothiol compounds |
| 09/12/2006 | US7105573 Administering to the mammal an insulin sensitivity increasing substance (ISIS) in an amount effective to treat the disorder in the mammal, in a manner so as to reach an affected area of the pilosebaceous apparatus |
| 09/12/2006 | US7105571 Substituted aminoalkanoate or substituted aminoalkyl alkanoate as a penetration enhancer a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. |
| 09/12/2006 | US7105561 Use of etodolac for the treatment of prostate cancer |
| 09/12/2006 | US7105560 Use of etodolac in the treatment of multiple myeloma |
| 09/12/2006 | US7105558 Gastrin and cholecystokinin receptor lignads (iv) |
| 09/12/2006 | US7105556 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 09/12/2006 | US7105548 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| 09/12/2006 | US7105546 Useful for treating or preventing neuronal damage associated with neurological diseases |
| 09/12/2006 | US7105540 Cholinesterase inhibitors to treat disorders of attention |
| 09/12/2006 | US7105523 Carbamate-substituted pyrazolopyridine-derivatives |
| 09/12/2006 | US7105519 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 09/12/2006 | US7105504 Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease |
| 09/12/2006 | US7105498 Increases bioavailability of uridine and cytidine; treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease; dosage forms |
| 09/12/2006 | US7105490 Methods and compositions for treating polycystic ovary syndrome |
| 09/12/2006 | US7105489 Methods and compositions for treating polycystic ovary syndrome |
| 09/12/2006 | US7105485 HO-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 09/12/2006 | US7105333 Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon |
| 09/12/2006 | US7105328 Methods for screening for compounds that modulate pd-1 signaling |
| 09/12/2006 | US7105317 Immunogenic compositions comprising vrg-gene products from Bordetella extracts |
| 09/12/2006 | US7105229 Dispersing a matrix of nanostructured liquid phase or a dehydrated variant and a nanostructured liquid crystalline phase or a dehydrated variant in nonlamellar material; cooling or evaporating a volatile solvent |
| 09/12/2006 | US7105185 Solvent extraction from plant using liquid carbon dioxide; therapy for muscular disorders |
| 09/12/2006 | US7105170 comprises in vitro granuloma model containing fibroblasts for drug screening vaccines; kits |
| 09/12/2006 | US7105167 Administering variants of insulin-like growth factor I to treat hyperglycemic disorder, congestive heart failure, urogenital disorders, poor nutrition, or a wasting syndrome |
| 09/12/2006 | US7105132 Liquid handlers, each includes a movable table that engages a sample multiwell plate and can align pipettes of the station with different subsets of wells of the multiwell plate where the number of wells is a multiple of the number of pipettes |
| 09/12/2006 | CA2346539C Compositions and methods for enhancing receptor-mediated cellular internalization |
| 09/12/2006 | CA2312545C Solid, thermoformable, controlled-release pharmaceutical compound |
| 09/12/2006 | CA2298259C Basic drug compositions with enhanced bioavailability |
| 09/12/2006 | CA2236598C Treatment of cardiomyopathy by removal of autoantibodies |
| 09/12/2006 | CA2167004C Agent for treating mental disorders associated with cerebrovascular disorders |
| 09/08/2006 | WO2006093784A2 Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents |
| 09/08/2006 | WO2006093211A1 Anti-viral agent |
| 09/08/2006 | WO2006093192A1 Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia |
| 09/08/2006 | WO2006093034A1 Mental disorder-related gene and use of the same |
| 09/08/2006 | WO2006092569A1 Production process for nsaid-containing lozenges, their compositions, their medicinal use |
| 09/08/2006 | WO2006030306A3 Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder |
| 09/08/2006 | WO2006029142A3 Methods and systems for treating asthma and other respiratory diseases |
| 09/08/2006 | WO2006021008A3 Ionophores as cancer chemotherapeutic agents |
| 09/08/2006 | WO2005032456A3 Tricalcium phosphates, their composites, implants incorporating them, and methods for their production |
| 09/08/2006 | WO2004091307A3 Feed additives against diseasse infection in terrestrial and aquatic animals |
| 09/08/2006 | WO2003028696A8 Compositions for delivery of drug combinations |
| 09/08/2006 | CA2599959A1 Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
| 09/08/2006 | CA2599861A1 Production process for nsaid-containing lozenges, their compositions, their medicinal use |
| 09/08/2006 | CA2598668A1 Dosage forms of antibiotics and combinations of antibiotics and symptomatic relief agents |
| 09/08/2006 | CA2586208A1 Human obesity susceptibility gene encoding potassium ion channels and uses thereof |
| 09/07/2006 | US20060200069 Transdermal drug delivery devices having coated microprotrusions |
| 09/07/2006 | US20060199978 Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders |
| 09/07/2006 | US20060199868 Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina |
| 09/07/2006 | US20060199866 Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse |
| 09/07/2006 | US20060199843 Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |